FDA Inspection 1082461 — Breckenridge Pharmaceutical, Inc
The FDA completed an inspection of Breckenridge Pharmaceutical, Inc on Jan 29, 2019 in Berlin, CT. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Jan 29, 2019
- Fiscal Year
- 2019
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Berlin, CT (United States)
Additional Details
Postmarket Adverse Drug Experience (PADE)